Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jason Sousa is active.

Publication


Featured researches published by Jason Sousa.


The New England Journal of Medicine | 2013

Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.

Jason W. Bennett; Brandon S. Pybus; Anjali Yadava; Donna Tosh; Jason Sousa; William F. McCarthy; Gregory Deye; Victor Melendez; Christian F. Ockenhouse

Primaquine is used to eradicate the hepatic or hypnozoite form of Plasmodium vivax that may lead to relapse of infection. Host genetic factors may play a role in the activity of primaquine therapy.


Malaria Journal | 2012

CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine

Brandon S. Pybus; Jason Sousa; Xiannu Jin; James A Ferguson; Robert E Christian; Rebecca Barnhart; Chau Vuong; Richard J. Sciotti; Gregory A. Reichard; Michael P. Kozar; Larry A. Walker; Colin Ohrt; Victor Melendez

BackgroundThe 8-aminoquinoline (8AQ) drug primaquine (PQ) is currently the only approved drug effective against the persistent liver stage of the hypnozoite forming strains Plasmodium vivax and Plasmodium ovale as well as Stage V gametocytes of Plasmodium falciparum. To date, several groups have investigated the toxicity observed in the 8AQ class, however, exact mechanisms and/or metabolic species responsible for PQ’s haemotoxic and anti-malarial properties are not fully understood.MethodsIn the present study, the metabolism of PQ was evaluated using in vitro recombinant metabolic enzymes from the cytochrome P450 (CYP) and mono-amine oxidase (MAO) families. Based on this information, metabolite identification experiments were performed using nominal and accurate mass measurements.ResultsRelative activity factor (RAF)-weighted intrinsic clearance values show the relative role of each enzyme to be MAO-A, 2C19, 3A4, and 2D6, with 76.1, 17.0, 5.2, and 1.7% contributions to PQ metabolism, respectively. CYP 2D6 was shown to produce at least six different oxidative metabolites along with demethylations, while MAO-A products derived from the PQ aldehyde, a pre-cursor to carboxy PQ. CYPs 2C19 and 3A4 produced only trace levels of hydroxylated species.ConclusionsAs a result of this work, CYP 2D6 and MAO-A have been implicated as the key enzymes associated with PQ metabolism, and metabolites previously identified as potentially playing a role in efficacy and haemolytic toxicity have been attributed to production via CYP 2D6 mediated pathways.


Bioorganic & Medicinal Chemistry Letters | 2010

Structure–activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum

Erin E. Milner; William McCalmont; Jayendra B. Bhonsle; Diana Caridha; Dustin Carroll; Sean Gardner; Lucia Gerena; Montip Gettayacamin; Charlotte A. Lanteri; ThuLan Luong; Victor Melendez; Jay Moon; Norma Roncal; Jason Sousa; Anchalee Tungtaeng; Peter Wipf; Geoffrey S. Dow

Utilizing mefloquine as a scaffold, a next generation quinoline methanol (NGQM) library was constructed to identify early lead compounds that possess biological properties consistent with the target product profile for malaria chemoprophylaxis while reducing permeability across the blood-brain barrier. The library of 200 analogs resulted in compounds that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Herein we report selected chemotypes and the emerging structure-activity relationship for this library of quinoline methanols.


Antimicrobial Agents and Chemotherapy | 2015

Differential CYP 2D6 Metabolism Alters Primaquine Pharmacokinetics

Brittney Potter; Lisa H. Xie; Chau Vuong; Jing Zhang; Ping Zhang; Dehui Duan; ThuLan Luong; H. M. T. Bandara Herath; N. P. Dhammika Nanayakkara; Babu L. Tekwani; Larry A. Walker; Christina K. Nolan; Richard J. Sciotti; Victor E. Zottig; Philip L. Smith; Robert Paris; Lisa T. Read; Qigui Li; Brandon S. Pybus; Jason Sousa; Gregory A. Reichard; Sean R. Marcsisin

ABSTRACT Primaquine (PQ) metabolism by the cytochrome P450 (CYP) 2D family of enzymes is required for antimalarial activity in both humans (2D6) and mice (2D). Human CYP 2D6 is highly polymorphic, and decreased CYP 2D6 enzyme activity has been linked to decreased PQ antimalarial activity. Despite the importance of CYP 2D metabolism in PQ efficacy, the exact role that these enzymes play in PQ metabolism and pharmacokinetics has not been extensively studied in vivo. In this study, a series of PQ pharmacokinetic experiments were conducted in mice with differential CYP 2D metabolism characteristics, including wild-type (WT), CYP 2D knockout (KO), and humanized CYP 2D6 (KO/knock-in [KO/KI]) mice. Plasma and liver pharmacokinetic profiles from a single PQ dose (20 mg/kg of body weight) differed significantly among the strains for PQ and carboxy-PQ. Additionally, due to the suspected role of phenolic metabolites in PQ efficacy, these were probed using reference standards. Levels of phenolic metabolites were highest in mice capable of metabolizing CYP 2D6 substrates (WT and KO/KI 2D6 mice). PQ phenolic metabolites were present in different quantities in the two strains, illustrating species-specific differences in PQ metabolism between the human and mouse enzymes. Taking the data together, this report furthers understanding of PQ pharmacokinetics in the context of differential CYP 2D metabolism and has important implications for PQ administration in humans with different levels of CYP 2D6 enzyme activity.


Malaria Journal | 2010

Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols

Erin E. Milner; William McCalmont; Jayendra B. Bhonsle; Diana Caridha; Jose Cobar; Sean Gardner; Lucia Gerena; Duane Goodine; Charlotte A. Lanteri; Victor Melendez; Norma Roncal; Jason Sousa; Peter Wipf; Geoffrey S. Dow

BackgroundThe clinical utility for mefloquine has been eroded due to its association with adverse neurological effects. Better-tolerated alternatives are required. The objective of the present study was the identification of lead compounds that are as effective as mefloquine, but exhibit physiochemical properties likely to render them less susceptible to passage across the blood-brain barrier.MethodsA library of drug-like non-piperidine analogs of mefloquine was synthesized. These compounds are diverse in structure and physiochemical properties. They were screened in appropriate in vitro assays and evaluated in terms of their potential as lead compounds. The correlation of specific structural attributes and physiochemical properties with activity was assessed.ResultsThe most potent analogs were low molecular weight unconjugated secondary amines with no heteroatoms in their side-chains. However, these compounds were more metabolically labile and permeable than mefloquine. In terms of physiochemical properties, lower polar surface area, lower molecular weight, more freely rotatable bonds and fewer H-bond acceptors were associated with greater potency. There was no such relationship between activity and LogP, LogD or the number of hydrogen bond donors (HBDs). The addition of an H-bond donor to the side-chain yielded a series of active diamines, which were as metabolically stable as mefloquine but showed reduced permeability.ConclusionsA drug-like library of non-piperidine analogs of mefloquine was synthesized. From amongst this library an active lead series of less permeable, but metabolically stable, diamines was identified.


Clinical Infectious Diseases | 2012

Prolonged Protection Provided by a Single Dose of Atovaquone-Proguanil for the Chemoprophylaxis of Plasmodium falciparum Malaria in a Human Challenge Model

Gregory Deye; R. Scott Miller; Lori Miller; Carola Salas; Donna Tosh; Louis Macareo; Bryan L. Smith; Susan Fracisco; Emily G. Clemens; Jittawadee Murphy; Jason Sousa; J. Stephen Dumler; Alan J. Magill

BACKGROUND We conducted a randomized, placebo-controlled, double-blind trial to establish the efficacy of atovaquone-proguanil to prevent malaria with the goal of simulating weekly dosing in a human Plasmodium falciparum challenge model. METHODS Thirty volunteers randomly received 1 of the following dose regimens: (1) 250 milligrams of atovaquone and 100 milligrams of proguanil (250/100 milligrams) 1 day prior to infectious mosquito challenge (day -1), (2) 250/100 milligrams on day 4 after challenge, (3) 250/100 milligrams on day -7, (4) 500 milligrams of atovaquone and 200 milligrams of proguanil (500/200 milligrams) on day -7 or, (5) 1000 milligrams of atovaquone and 400 milligrams of proguanil (1000/400 milligrams) on day -7. All regimens included matching placebo such that all volunteers received identical pill numbers. Six volunteers served as open-label infectivity controls. Volunteers underwent mosquito sporozoite challenge with P. falciparum 3D7 strain. Follow-up consisted of serial microscopy and close clinical monitoring for 90 days. RESULTS Six of 6 infectivity controls developed parasitemia as expected. Two of 5 evaluable volunteers receiving 250/100 milligrams 7 days prior to challenge and 1 of 6 volunteers receiving 1000/400 milligrams 7 days prior to challenge were microscopically diagnosed with malaria. All other volunteers were protected. Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success). Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success). CONCLUSIONS Single-dose atovaquone-proguanil provides effective malaria chemoprophylaxis against P. falciparum challenge at dosing intervals supportive of weekly dosing. Postexposure prophylaxis 4 days after challenge was 100% effective.


Malaria Journal | 2011

Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice

Geoffrey S. Dow; Erin E. Milner; Ian Bathurst; Jayendra B. Bhonsle; Diana Caridha; Sean Gardner; Lucia Gerena; Michael P. Kozar; Charlotte A. Lanteri; Anne Mannila; William McCalmont; Jay Moon; Kevin D. Read; Suzanne Norval; Norma Roncal; David M. Shackleford; Jason Sousa; Jessica Steuten; Karen L. White; Qiang Zeng; Susan A. Charman

BackgroundThe clinical use of mefloquine (MQ) has declined due to dose-related neurological events. Next generation quinoline methanols (NGQMs) that do not accumulate in the central nervous system (CNS) to the same extent may have utility. In this study, CNS levels of NGQMs relative to MQ were measured and an early lead chemotype was identified for further optimization.Experimental designThe plasma and brain levels of MQ and twenty five, 4-position modified NGQMs were determined using LCMS/MS at 5 min, 1, 6 and 24 h after IV administration (5 mg/kg) to male FVB mice. Fraction unbound in brain tissue homogenate was assessed in vitro using equilibrium dialysis and this was then used to calculate brain-unbound concentration from the measured brain total concentration. A five-fold reduction CNS levels relative to mefloquine was considered acceptable. Additional pharmacological properties such as permeability and potency were determined.ResultsThe maximum brain (whole/free) concentrations of MQ were 1807/4.9 ng/g. Maximum whole brain concentrations of NGQMs were 23 - 21546 ng/g. Maximum free brain concentrations were 0.5 to 267 ng/g. Seven (28%) and two (8%) compounds exhibited acceptable whole and free brain concentrations, respectively. Optimization of maximum free brain levels, IC90s (as a measure or potency) and residual plasma concentrations at 24 h (as a surrogate for half-life) in the same molecule may be feasible since they were not correlated. Diamine quinoline methanols were the most promising lead compounds.ConclusionReduction of CNS levels of NGQMs relative to mefloquine may be feasible. Optimization of this property together with potency and long half-life may be feasible amongst diamine quinoline methanols.


Journal of Medicinal Chemistry | 2011

Structure–Activity Relationships of 4-Position Diamine Quinoline Methanols as Intermittent Preventative Treatment (IPT) against Plasmodium falciparum

Erin E. Milner; Sean Gardner; Jay Moon; Kristina Grauer; Jennifer M. Auschwitz; Ian C. Bathurst; Diana Caridha; Lucia Gerena; Montip Gettayacamin; Jacob D. Johnson; Michael P. Kozar; Patricia J. Lee; Susan E. Leed; Qigui Li; William McCalmont; Victor Melendez; Norma Roncal; Richard J. Sciotti; Bryan Smith; Jason Sousa; Anchalee Tungtaeng; Peter Wipf; Geoffrey S. Dow

A library of diamine quinoline methanols were designed based on the mefloquine scaffold. The systematic variation of the 4-position amino alcohol side chain led to analogues that maintained potency while reducing accumulation in the central nervous system (CNS). Although the mechanism of action remains elusive, these data indicate that the 4-position side chain is critical for activity and that potency (as measured by IC(90)) does not correlate with accumulation in the CNS. A new lead compound, (S)-1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(2-(cyclopropylamino)ethylamino)ethanol (WR621308), was identified with single dose efficacy and substantially lower permeability across MDCK cell monolayers than mefloquine. This compound could be appropriate for intermittent preventative treatment (IPTx) indications or other malaria treatments currently approved for mefloquine.


European Journal of Drug Metabolism and Pharmacokinetics | 2012

Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy

Erin E. Milner; Jason Sousa; Brandon S. Pybus; Jennifer M. Auschwitz; Diana Caridha; Sean Gardner; Kristina Grauer; Erin Harris; Mark Hickman; Michael P. Kozar; Patricia J. Lee; Susan E. Leed; Qigui Li; Victor Melendez; Jay Moon; Franklyn Ngundam; Michael T. O’Neil; Sandi Parriott; Brittney Potter; Rick Sciotti; Anchalee Tangteung; Geoffrey S. Dow

Ketotifen is known to exhibit antimalarial activity in mouse and monkey malaria models. However, the low plasma levels and short half life of the drug do not adequately explain its in vivo efficacy. We synthesized most of the known metabolites of ketotifen and evaluated their antimalarial activity and pharmacokinetics in mice. Norketotifen, the de-methylated metabolite of ketotifen, was a more potent antimalarial in vitro as compared to ketotifen, and exhibited equivalent activity in vivo against asexual blood and developing liver-stage parasites. After ketotifen dosing, norketotifen levels were much higher than ketotifen relative to the IC50s of the compounds against Plasmodium falciparum in vitro. The data support the notion that the antimalarial activity of ketotifen in mice is mediated through norketotifen.


Antimicrobial Agents and Chemotherapy | 2015

Differential Cytochrome P450 2D Metabolism Alters Tafenoquine Pharmacokinetics

Chau Vuong; Lisa H. Xie; Brittney Potter; Jing Zhang; Ping Zhang; Dehui Duan; Christina K. Nolan; Richard J. Sciotti; Victor E. Zottig; N. P. Dhammika Nanayakkara; Babu L. Tekwani; Larry A. Walker; Philip L. Smith; Robert Paris; Lisa T. Read; Qigui Li; Brandon S. Pybus; Jason Sousa; Gregory A. Reichard; Bryan Smith; Sean R. Marcsisin

ABSTRACT Cytochrome P450 (CYP) 2D metabolism is required for the liver-stage antimalarial efficacy of the 8-aminoquinoline molecule tafenoquine in mice. This could be problematic for Plasmodium vivax radical cure, as the human CYP 2D ortholog (2D6) is highly polymorphic. Diminished CYP 2D6 enzyme activity, as in the poor-metabolizer phenotype, could compromise radical curative efficacy in humans. Despite the importance of CYP 2D metabolism for tafenoquine liver-stage efficacy, the exact role that CYP 2D metabolism plays in the metabolism and pharmacokinetics of tafenoquine and other 8-aminoquinoline molecules has not been extensively studied. In this study, a series of tafenoquine pharmacokinetic experiments were conducted in mice with different CYP 2D metabolism statuses, including wild-type (WT) (reflecting extensive metabolizers for CYP 2D6 substrates) and CYPmouse 2D knockout (KO) (reflecting poor metabolizers for CYP 2D6 substrates) mice. Plasma and liver pharmacokinetic profiles from a single 20-mg/kg of body weight dose of tafenoquine differed between the strains; however, the differences were less striking than previous results obtained for primaquine in the same model. Additionally, the presence of a 5,6-ortho-quinone tafenoquine metabolite was examined in both mouse strains. The 5,6-ortho-quinone species of tafenoquine was observed, and concentrations of the metabolite were highest in the WT extensive-metabolizer phenotype. Altogether, this study indicates that CYP 2D metabolism in mice affects tafenoquine pharmacokinetics and could have implications for human tafenoquine pharmacokinetics in polymorphic CYP 2D6 human populations.

Collaboration


Dive into the Jason Sousa's collaboration.

Top Co-Authors

Avatar

Brandon S. Pybus

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Sean R. Marcsisin

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Victor Melendez

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Qigui Li

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Diana Caridha

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Michael P. Kozar

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Gregory A. Reichard

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Brittney Potter

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Erin E. Milner

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Larry A. Walker

University of Mississippi

View shared research outputs
Researchain Logo
Decentralizing Knowledge